NCT05601830 2024-11-06
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Terminated
Institute of Hematology & Blood Diseases Hospital, China
Therapeutic Advances in Childhood Leukemia Consortium